MARIA MEZA: Open Payments
NPI 1962070839 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 58 payments from 13 companies in 2025. Trend: 2023 $526 · 2024 $625 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 19 | $239 |
| Ardelyx, Inc. | 9 | $180 |
| Calliditas Therapeutics US Inc. | 4 | $101 |
| Travere Therapeutics, Inc. | 7 | $98 |
| Novo Nordisk Inc | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| SCPHARMACEUTICALS INC. | 2 | $30 |
Products named: Kerendia, IBSRELA, TARPEYO, JARDIANCE, FARXIGA, BENLYSTA, Wegovy, VOYXACT.
Industry payments across TX — which companies pay providers there.
